Overview

Metformin for the Prevention of Episodic Migraine (MPEM)

Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
The investigators will evaluate the safety and efficacy of metformin for preventive treatment of migraine in a randomized, double-blind, placebo-controlled, crossover trial.
Phase:
Phase 3
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Metformin